読み込み中
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
前日終値
$0.13
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日中レンジ
現在 $0.13
52週レンジ
現在 $0.13
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
21
割高
センチメント
53
まちまち
リスク
66
高リスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日中レンジ
現在 $0.13
52週レンジ
現在 $0.13
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 26.9万 USD | 30万 USD | 18.9万 USD | 27万 USD |
| 売上原価 | 68.4万 USD | 193.7万 USD | 130.6万 USD | 87.5万 USD | 115.8万 USD |
| 粗利益 | −68.4万 USD | −166.8万 USD | −100.6万 USD | −68.6万 USD | −88.8万 USD |
| 研究開発 | 1063.9万 USD | 463.4万 USD | 1539.9万 USD | 1785.5万 USD | 1535.5万 USD |
| 販売・一般管理 | 1056.7万 USD | 697.6万 USD | 1153.7万 USD | 537.2万 USD | 440.2万 USD |
| 営業費用 | 2120.6万 USD | 6081.2万 USD | 2693.6万 USD | 2322.7万 USD | 1975.7万 USD |
| 受取利息 | 47.7万 USD | 42.3万 USD | 3000 USD | 3.9万 USD | 3000 USD |
| 支払利息 | 290.6万 USD | −110.2万 USD | 165.9万 USD | 13.7万 USD | — |
| 減価償却費と償却費 | 97万 USD | 138.6万 USD | 53.2万 USD | 49.5万 USD | 33.6万 USD |
| 営業利益 | −2189万 USD | −6248万 USD | −2794.2万 USD | −2391.3万 USD | −2064.5万 USD |
| 純利益 | −2508.4万 USD | −5376.3万 USD | −3814.6万 USD | −2367.3万 USD | −1993.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$3.00
上昇余地（2207.69%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
